Glyphase M2 Tablet SR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, formulated for sustained release to provide effective glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The sustained-release formulation allows for a gradual absorption, minimizing gastrointestinal side effects commonly associated with metformin and improving patient compliance through once or twice-daily dosing. Glyphase M2 is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when monotherapy with either agent is inadequate. It should be used with caution in patients with renal or hepatic impairment and is contraindicated in conditions predisposing to lactic acidosis. Regular monitoring of blood glucose and renal function is recommended during therapy. This combination offers a complementary mechanism of action, addressing multiple pathophysiological defects of type 2 diabetes, thus optimizing glycemic management and reducing the risk of diabetes-related complications.